CDK17 exhibits high expression in several tumor samples compared to their normal counterparts, including cholangiocarcinoma (CHOL), diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD), and thymoma (THYM) [112]. Here, CDK17 is linked to pancreatic adenocarcinoma.